Clinical Trials Logo

Filter by:
NCT ID: NCT00734032 Completed - Atherosclerosis Clinical Trials

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

Start date: August 26, 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.

NCT ID: NCT00733161 Completed - Clinical trials for Congestive Heart Failure

Effect of Passive Exercise on Systemic Endothelial Function in Elderly Patients With Chronic Heart Failure

Start date: August 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of passive exercise on systemic endothelial function in elderly patients with chronic heart failure.

NCT ID: NCT00732992 Completed - Neoplasm, Malignant Clinical Trials

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Start date: August 2008
Phase: Phase 1
Study type: Interventional

This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.

NCT ID: NCT00731445 Completed - Clinical trials for Advanced Hepatocellular Carcinoma

Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II is studying the side effect and best dose of Z-208 for patients with advanced hepatocellular carcinoma

NCT ID: NCT00727987 Completed - Clinical trials for Rheumatoid Arthritis

A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite Methotrexate therapy. Another objective is to evaluate the pharmacokinetics of golimumab.

NCT ID: NCT00726752 Completed - Neoplasms Clinical Trials

A Study In Patients With Advanced Solid Tumor

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

NCT ID: NCT00724971 Completed - Lymphoma, B-Cell Clinical Trials

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Start date: July 4, 2008
Phase: Phase 1
Study type: Interventional

To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL).

NCT ID: NCT00724776 Completed - Chronic Hepatitis C Clinical Trials

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients

NCT ID: NCT00723528 Completed - Psoriasis Clinical Trials

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Start date: March 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275) compared with placebo in participants with moderate to severe plaque type psoriasis.

NCT ID: NCT00723216 Completed - Abdominal Neoplasms Clinical Trials

Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery. The secondary objective is evaluate the incidence of adverse events of enoxaparin in these patients.